Once described as “throwing processes over the wall,” tech transfer is evolving into close collaboration and communication, as potential problems are considered sooner, and new technology is applied. Joseph Szczesiul, director of technical services for UPM Pharmaceuticals, shares best practices.
Drawing on practical experience, the authors examine key questions and answers about various aspects relating to the enhanced approach for analytical procedure lifecycle management.
EMA’s relocation to Amsterdam and resulting staff losses could severely weaken the agency’s role as a leading medicines regulator.
Three hypothetical analytical target profiles (ATPs) are provided, reflecting the current thinking of the the European Federation of Pharmaceutical Industries and Associations Analytical Lifecycle Management Team.
GMP non-compliance can spill over and impact patient access to life-saving medications.
Owner of Immuno Biotech, David Noakes, has been sentenced to 15 months in prison over charges of manufacturing, selling, and supplying an unlicensed medicine, as well as money laundering.
Five additional European Union member states have been confirmed by the US Food and Drug Administration (FDA) as capable of performing good manufacturing practice inspections at a level equivalent to that of the United Sates
Pharmaceutical Technology's In the Lab eNewsletter
A new, high-throughput microplate reader cuts down on screening time and works faster than standard ultra-high-performance liquid chromatography processes.
Pharmaceutical Technology's In the Lab eNewsletter
The partnership, co-funded by Enterprise Ireland, will develop technologies for monitoring the quality of biopharma processes.
Despite ongoing efforts to address the problem, FDA now sees a rise in active shortages and in the duration of supply problems.
The agency has approved two new chemical entities, Daurismo (glasdegib) from Pfizer, and Vitrakvi (larotrectinib) from Loxo Oncology, for treating cancers.
FDA has issued a warning letter to Mylan citing GMP violations of finished pharmaceutical products manufactured at the company’s Morgantown, WV, facility.
The positive opinions included the first oral-only tablet for the treatment of human African trypanosomiasis.
After a review of serious side effects, the agency decided to suspend marketing authorizations for quinolone and fluoroquinolone antibiotics and restrict use of remaining fluoroquinolone antibiotics.
Moving forward with gene therapy development requires a “quantum leap” in manufacturing capabilities.
The agency provided an update on its relocation plans and assured that core activities are continuing uninterrupted.
The new good pharmacovigilance practice chapter IV on specific considerations for the pediatric population offers a holistic view of pediatric pharmacovigilance and provides guidance on how to address the specific needs and challenges of safety monitoring of medicines used in children.
This article discusses why it is important to apply risk analysis, QbD, and DoE in the development of analytical methods.
Rather than isolating the user in a virtual world, mixed reality allows contextualized data to be shared in real time, improving assays, standard operating procedures, workflows, and overall tech transfer.
The agency sent a warning letter to the company for marketing an unapproved stem cell product and CGMP violations.
The agency is developing a new way to assess, record, and report data from surveillance and preapproval inspections of sterile drugs.
Pharma companies are concerned they may have to postpone plans for the commercialization of new combination products because of delays in obtaining marketing authorizations because of a lack of clarity about approval rules.
Investigatory work arranged by Swissmedic has revealed that sartan-containing medicines on the Swiss market are safe in respect of NDMA.
The new program will provide cell and gene therapy companies a more efficient way to ensure quality compliance across collection center networks and to minimize quality system audit burden on these centers.
Leaders of the two parties are open to challenging the status quo on drug costs and spending.
